SecBot SecBot

GRFS drug pipeline

Grifols SA · 1 rated drug
$8.69
−1.3% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 neutral
Phase 3 trials
1
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved (marketed); new Phase 3 label-expansion trial (SIGMA) just begun enrolling
Time to marketAlready on the market (approved and commercialized). Label expansion into secondary immunodeficiency is estimated years away — readouts likely 2-3 years out per company commentary.

GAMUNEX-C immune globulin intravenous (human) Updated Aug 18

What to watch

For Grifols (GRFS), Gamunex-C is a core revenue asset but not a near-term stock catalyst, the share-price drivers in the next ~12 months are company-wide (SPARTA Prolastin-C topline expected by end-2026, quarterly results), not Gamunex-C-specific. Watch SIGMA/XPERT enrollment updates for optionality, but treat the label-expansion payoff as a 2028+ event. Note the tape is mixed: positive analyst consensus and Q2 2026 13F accumulation by several managers, but also high short-volume flow and multiple 13F trims/exits.

Bull case
  • Already-approved, marketed flagship product generating revenue today; Grifols calls GAMUNEX-C and XEMBIFY its 'flagship immunoglobulins' and cites XEMBIFY growing nearly 60% YoY in 2025 as evidence of strong Ig-franchise demand (July 16, 2026 press release).
  • New Phase 3 SIGMA trial targets secondary immunodeficiency in hematologic cancers, a population of >1 million U.S. patients with CLL, MM and NHL, a meaningful label-expansion opportunity if it succeeds (press release report key facts).
  • Analyst setup positive: consensus 9 Buy + 5 Strong Buy vs 2 Sell/5 Hold, and mean price target $10.865 vs $7.75 last price (~40.2% implied upside), though based on only 2 analysts' targets.
Bear case
  • No near-term binary for THIS drug: SIGMA/XPERT are just starting enrollment (first dose July 2026) with readouts estimated 2-3 years out, so label-expansion revenue is far away (press release report actionableInsight).
  • Phase 3 and regulatory risk: trial failure or enrollment delays could derail label expansion, and Ig products carry safety risks such as thrombotic events (press release report risk list).
  • Competition: CSL Behring, Takeda and others market competing immunoglobulin therapies that could limit share gains even if labels expand (press release report risk list).

Other drugs in filings and trials

no drug report yet

Clinical trials

2 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
Alpha-1 MPEfficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)Phase 3Completed345Jul 7, 2026
Alpha-1 15%A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin DeficiencyPhase 2Completed · results17Aug 1, 2025